Press Release
<< Back
Verastem to Present Data at the 16th World Conference on Lung Cancer
The details for the data presentations at WCLC are as follows:
Oral Presentations
Title: Phase 2 study of defactinib, VS-6063, a focal adhesion
kinase (FAK) inhibitor, in patients with KRAS mutant non-small cell lung
cancer (NSCLC)
Date and time:
Location: Four
Session info: Mini oral 30: New Kinase Targets; Track:
Treatment of Advanced Diseases - NSCLC
Title: FAK inhibitor VS-6063 targets mesothelioma cancer stem
cells: Rationale for maintenance therapy after conventional chemotherapy
Date
and time:
Location:
Rooms 702, 704 and 706
Session info: Mini oral 38: Biology
and Prognosis; Track: Thymoma, Mesothelioma and Other Thoracic
Malignancies
Title: The cancer stem cell inhibitors VS-6063 (defactinib) and
VS-5584 exhibit synergistic anticancer activity in pre-clinical models
of mesothelioma
Date and time:
Location: Rooms 702, 704 and 706
Session
info: Oral session 40: Biology 1; Track: Thymoma, Mesothelioma and
Other Thoracic Malignancies
Title: Targeting cancer stem cells in small cell lung cancer
Date
and time:
Location:
Rooms 605 and 607
Session info: Mini oral 27: Biology and
other issues in SCLC; Track: Small Cell Lung Cancer
Poster Presentations
Title: Trials in progress: A Phase 1 dose escalation study of
VS-5584, a PI3K/mTOR inhibitor, administered with VS-6063, a focal
adhesion kinase inhibitor, in mesothelioma
Date and time:
Location:
Exhibit Hall (Hall B+C); Poster # P2.08.008
Session info:
Thymoma, Mesothelioma and Other Thoracic Malignancies – Mesothelioma
Title: Trials in progress: COMMAND: A Phase 2 randomized,
double-blind, study of defactinib (VS-6063) as maintenance therapy in
malignant pleural mesothelioma
Date and time:
Location:
Exhibit Hall (Hall B+C); Poster # P3.08.014
Session info:
Thymoma, Mesothelioma and Other Thoracic Malignancies – Mesothelioma
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a “Window of Opportunity” study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, a trial in patients with KRAS-mutated non-small cell lung cancer and a trial evaluating the combination of VS-6063 and VS-5584 in patients with relapsed mesothelioma. VS-6063 has been granted orphan drug designation for use in mesothelioma in the U.S. and EU.
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and
highly selective activity against class 1 PI3K enzymes and dual
inhibitory actions against mTORC1 and mTORC2. In preclinical studies,
VS-5584 has been shown to reduce the percentage of cancer stem cells and
induce tumor regression in chemotherapy-resistant models.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063, VS-4718 and VS-5584, and the Company’s FAK,
PI3K/mTOR and diagnostics programs generally and the structure of our
planned or pending clinical trials. The words “anticipate,” “appear,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s product candidates and preliminary
or interim data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that data may
not be available when we expect it to be, that enrollment of clinical
trials may take longer than expected, that our product candidates will
cause unexpected safety events, that the Company will be unable to
successfully initiate or complete the clinical development of its
product candidates, that the development of the Company’s product
candidates will take longer or cost more than planned, and that the
Company’s product candidates will not receive regulatory approval or
become commercially successful products. Other risks and uncertainties
include those identified under the heading “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20150826005239/en/
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com
